Avanos director granted 12,003 restricted units

Egbuonu-Davis Lisa reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Egbuonu-Davis Lisa reported acquisition or exercise transactions in this Form 4 filing.

Avanos Medical, Inc. director Lisa Egbuonu-Davis received a grant of 12,003 restricted share units on May 8, 2026. Each unit provides a contingent right to a cash payment equal to the value of one share of Avanos common stock.

The new restricted share units fully replace an earlier grant made on January 2, 2025. These units vest when Egbuonu-Davis terminates her service on the company’s Board of Directors. After this grant, she holds 12,003 restricted share units directly as reported in this filing.

Insider Trade Summary

Grant/Award: 12,003 shares

Grant/Award 1 txn

Insider Egbuonu-Davis Lisa

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	12,003	$0.00	$0.00

Holdings After Transaction: Restricted Share Units — 12,003 contracts (Direct)

Footnotes (2)

1. F1. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025.
2. F2. The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors.

Key Figures

RSUs granted: 12,003 units Exercise price: $0.00 per unit Underlying shares reference: 12,003 shares +2 more

5 metrics

RSUs granted 12,003 units Restricted share units granted on May 8, 2026

Exercise price $0.00 per unit Conversion or exercise price for the restricted share units

Underlying shares reference 12,003 shares Each unit references the value of one share of common stock

Holdings after grant 12,003 units Total restricted share units held following the reported transaction

Grant date May 8, 2026 Date the restricted share units were issued

Key Terms

Restricted Share Units, contingent right, vest, Board of Directors

4 terms

Restricted Share Units financial

"Represents restricted share units issued to the Reporting Person on May 8, 2026."

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share"

vest financial

"The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Board of Directors financial

"The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors."

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Avanos Medical (AVNS) report for Lisa Egbuonu-Davis?

Avanos Medical reported that director Lisa Egbuonu-Davis received 12,003 restricted share units on May 8, 2026. These units are cash-settled awards tied to the value of Avanos common stock and serve as part of her board-level compensation package.

How many restricted share units did the Avanos Medical (AVNS) director receive?

Lisa Egbuonu-Davis received 12,003 restricted share units in this Form 4 filing. Each restricted share unit represents a right to a cash payment equal to the value of one share of Avanos common stock upon vesting, rather than delivering actual shares.

When do Lisa Egbuonu-Davis’s Avanos Medical (AVNS) restricted share units vest?

The restricted share units for Lisa Egbuonu-Davis vest when she terminates service on Avanos Medical’s Board of Directors. Vesting is therefore tied to the end of her board tenure, aligning the award with her period of governance service.

Are the Avanos Medical (AVNS) restricted share units share-settled or cash-settled?

The restricted share units granted to Lisa Egbuonu-Davis are cash-settled. Each unit provides a contingent right to receive a cash payment equal to the value of one share of Avanos Medical common stock rather than delivering actual equity.

Did the Avanos Medical (AVNS) Form 4 reflect open-market buying or selling?

No open-market buying or selling was reported in this Form 4. The filing shows a compensation-related grant of restricted share units to director Lisa Egbuonu-Davis, not a purchase or sale of Avanos Medical shares in the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/12/2026 - 11:41 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Egbuonu-Davis Lisa

(Last) (First) (Middle)

5405 WINDWARD PKWY

(Street)

ALPHARETTA GEORGIA 30004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	05/08/2026		A		12,003		(2)	(2)	Common Stock	12,003	$0	12,003	D

Explanation of Responses:

1. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock. The restricted share units were issued to replace the restricted share units issued to the Reporting Person on January 2, 2025.

2. The restricted share units vest on the date the Reporting Person terminates service on the Issuer's Board of Directors.

Remarks:

	/s/ John Fischer, as attorney-in-fact for Lisa Egbuonu-Davis	05/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)